Last reviewed · How we verify

NCT06863454

Trichoscopy as a Monitoring Tool for Activity and Remission in Pemphigus Vulgaris: A Clinical Study Supported by Immunological Evaluation.

Not yet recruiting Last updated 7 March 2025
What this trial tests

trial testing Trichoscopy in Pemphigus Vulgaris (PV) in 62 participants. Not yet recruiting.

Timeline
1 May 2025
Primary endpoint
1 May 2026
1 May 2026

Quick facts

Lead sponsorAssiut University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment62
Start date1 May 2025
Primary completion1 May 2026
Estimated completion1 May 2026

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Pemphigus Vulgaris (PV). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pemphigus vulgaris (PV) is a potential life-threatening autoimmune bullous disorder presenting with multiple erosions and flaccid blisters that can involve both mucous membrane and skin. The microscopic findings include intraepithelial blisters caused by acantholysis of keratinocytes as the consequence of autoantibody formation. The antibodies are mainly IgG autoantibodies mostly directed against desmoglein 1 and 3 (Dsg 1, 3), which are adhesion molecules expressed on the surface of keratinocytes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Trichoscopy

Trials testing the same drug.

Other recruiting trials for Pemphigus Vulgaris (PV)

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06863454.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing